Análisis Argos
MRNA
MRNASin veredicto2 señales de riesgo
Moderna, Inc. · Healthcare
US$ 79.76
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
18/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Piotroski F-Score débil (3/9)
!FCF negativo con deuda creciente
VALOR0/6FUTURO6/6PASADO0/6SALUD2/6DIVIDENDO1/6
El Iris de calidad
VALOR0/6FUTURO6/6PASADO0/6SALUD2/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance razonable
DividendoEl dividendo aún duerme
Score Argos18de 100Sin veredicto
Ingresos▼39%
US$ 1.9 B
Margen operativo▲28%
-158.1%
Flujo de caja libre▼49%
US$ -2.1 B
Deuda neta
US$ -0.7 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 31.6B
P/E—
EV/EBITDA—
FCF yield-6.5%
ROIC-38.6%
Margen operativo-158.1%
Crecim. ingresos-39.2%/año
Piotroski F3/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

fool.com · 30 jun
Is Moderna Stock a No-Brainer Buy After a Key FDA Win?
On June 16, Moderna announced major news regarding one of its most highly anticipated follow-up products: an mRNA-based flu vaccine. The biotech company has also made some other promising announcements in recent weeks.
zacks.com · 29 jun
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
benzinga.com · 29 jun
Stock Of The Day: Will The Moderna Rally Continue?
Moderna, Inc.  (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday's gain of more than 12%.
invezz.com · 26 jun
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spanning oncology, autoimmune diseases, and next-generation mRNA therapies.
247wallst.com · 26 jun
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer.
barrons.com · 26 jun
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
feeds.newsfilecorp.com · 26 jun
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors
fool.com · 26 jun
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst
It's not just a "pandemic stock," after all.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.